Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | PPARD | Q03181 | 3/20 | 0.39 |
| ▸ | OGA | O60502 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12619638 | 0.91 | PPARG (0.37) | PPARGPPARDOGAGPR119NR1I2 | |
| SCHEMBL12269515 | 0.86 | PPARG (0.36) | PPARGPPARDOGAGPR119NR1I2 | |
| SCHEMBL13021436 | 0.84 | PPARG (0.43) | PPARGPPARDOGAGPR119NR1I2 | |
| SCHEMBL13021438 | 0.82 | PPARG (0.39) | PPARGPPARDOGAGPR119NR1I2 | |
| SCHEMBL1665706 | 0.82 | PPARG (0.42) | PPARGPPARDOGAGPR119NR1I2 | |
| SCHEMBL9986408 | 0.81 | GPR119 (0.45) | GPR119NR1I2 | |
| SCHEMBL10327520 | 0.81 | NR1I2 (0.43) | PPARGPPARDOGAGPR119NR1I2 | |
| SCHEMBL14491320 | 0.81 | NR1I2 (0.43) | PPARGPPARDOGAGPR119NR1I2 | |
| SCHEMBL1664257 | 0.80 | PPARG (0.37) | PPARGPPARDOGAGPR119NR1I2 | |
| SCHEMBL12796417 | 0.80 | PPARG (0.37) | PPARGPPARDOGAGPR119NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149530-A1 | For treatment of picornavirus infections in mammals | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149530-A1 | For treatment of picornavirus infections in mammals | HAVCR2, EIF2AK2, MAVS | PPARG 1962/4885PPARD 2564/4885OGA 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.